Bioventus price target raised to $17 from $12 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Bioventus to $17 from $12 and keeps a Buy rating on the shares following recent checks and positive impressions from recent investor meetings. There are strong tailwinds across the company’s portfolio, and Craig-Hallum sees upside to Street estimates as a result, the analyst tells investors in a research note. Craig-Hallum believes the company remains on track to divest the Advanced Rehab business.